Low-Dose Peanut Oral Immunotherapy: Safe and Effective 30 mg Treatment for Children with Peanut Allergy

Peanut allergy is one of the most common food allergies affecting children and adults worldwide. In Canada alone, almost 2% of children and 1.5% of adults are affected. Despite efforts at avoidance, accidental exposures occur frequently, with one study noting a 12.4% accidental exposure rate among children with peanut allergy. Historically, the main treatment approach for peanut allergy has been strict avoidance and readiness for emergency interventions such as epinephrine use. However, accidental exposures can still result in severe allergic reactions, including anaphylaxis, highlighting the need for effective preventive strategies.

Peanut oral immunotherapy (P-OIT) has emerged as a promising approach to desensitize patients to peanut protein. By gradually introducing small amounts of peanut protein into the diet, P-OIT aims to increase the threshold of allergic reactions, allowing patients to tolerate larger amounts of peanut without severe reactions. Traditional P-OIT studies have used relatively high maintenance doses, often around 300 mg to 4,000 mg of peanut protein per day, equivalent to two to 32 peanuts. While effective in increasing tolerance, these higher doses are associated with a significant risk of allergic reactions, frequent clinical visits, and high dropout rates.

A recent prospective randomized controlled trial led by Julia E. M. Upton and colleagues investigated whether very low-dose P-OIT could be a safe and effective alternative. This study evaluated the efficacy and safety of 30 mg versus 300 mg peanut protein maintenance doses in children with peanut allergy, with a comparison to a group following avoidance alone.

Study Design and Participants

The trial was conducted at two academic centers in Canada from 2018 to 2024. Fifty-one children aged 2 to 18 years with confirmed peanut allergy participated in the study. Participants were reactive to 444 mg or less of peanut protein during initial double-blind placebo-controlled food challenges (DBPCFC). Children were randomly assigned to one of three groups. Two groups received double-blind P-OIT with target maintenance doses of either 30 mg or 300 mg peanut protein. The third group followed an open-label avoidance protocol.

Participants underwent a modified rush initial desensitization protocol starting with 0.5 mg of peanut protein and escalating doses until reaching the target maintenance dose. The process included daily at-home doses and regular clinic visits for monitoring and up-dosing. Safety precautions were emphasized, including avoidance of physical activity for two hours after dosing and access to epinephrine autoinjectors.

Primary Outcomes and Efficacy

The primary outcomes focused on desensitization, measured by the proportion of participants able to tolerate cumulative doses of 443 mg and 1,043 mg or greater of peanut protein compared with the avoidance group. Secondary outcomes included immunologic markers such as serum-specific IgE and IgG4 levels.

Results showed that low-dose P-OIT at 30 mg daily was highly effective. In the 30 mg group, 76.5% of participants tolerated 443 mg or more of peanut protein, and 41.2% tolerated 1,043 mg or more. The 300 mg group had similar outcomes, with 58.8% tolerating 443 mg or more and 47.1% tolerating 1,043 mg or more. In contrast, none of the participants in the avoidance group tolerated these amounts, demonstrating that even a low maintenance dose can significantly increase the threshold of allergic reactions.

Both P-OIT groups showed significant improvements in cumulative tolerated doses compared to baseline, while the avoidance group did not show any change. This indicates that daily ingestion of even a small amount of peanut protein can induce meaningful clinical desensitization.

Immunologic Findings

P-OIT was associated with favorable immunologic changes. Skin prick test (SPT) results showed suppression in both P-OIT groups. In the 30 mg group, median SPT diameter decreased from 8 mm at baseline to 5 mm at the post-escalation food challenge. The 300 mg group saw a decrease from 7.5 mm to 4.25 mm. These reductions indicate a diminished allergic response.

Serum-specific IgG4 levels increased significantly in both groups, while specific IgE levels remained largely unchanged. The ratio of IgG4 to IgE, an important marker of desensitization, increased significantly for peanut protein in the 30 mg group and showed a trend toward increase in the 300 mg group. Basophil activation tests further supported desensitization, showing reduced sensitivity to peanut allergens in both treatment groups. These findings demonstrate that low-dose P-OIT not only improves clinical tolerance but also induces beneficial immunologic changes similar to higher-dose protocols.

Safety Profile

Safety is a critical consideration in P-OIT due to the risk of allergic reactions. Over 11,000 doses were administered in the trial, with an overall reaction rate of 4.8%. Most reactions were mild, including local oral symptoms such as itching and tingling, as well as gastrointestinal discomfort.

Systemic allergic reactions were less frequent in the 30 mg group compared to the 300 mg group. Moderate or severe non-anaphylactic reactions were 2.5 times more common in the 300 mg group, while rates of moderate or severe anaphylaxis were similar between groups. Importantly, no participants in the 30 mg group withdrew due to adverse events, while three withdrawals occurred in the 300 mg group. These findings highlight the improved safety and tolerability of low-dose P-OIT.

Summary Table of Key Outcomes

Clinical Implications

The trial demonstrates that very low-dose P-OIT at 30 mg daily, equivalent to about one-eighth of a peanut, can effectively increase tolerance to peanut protein in children with peanut allergy. This low-dose approach offers several potential advantages over higher-dose regimens.

Safety and Adherence: Lower doses are associated with fewer systemic reactions and improved safety, which can enhance adherence and reduce treatment dropout rates. The simplicity of administering a small, easily measurable dose without the need for complex up-dosing schedules can encourage long-term compliance.

Efficacy: Despite being only one-tenth of the traditional 300 mg maintenance dose, the 30 mg dose provided comparable increases in cumulative tolerated doses and induced favorable immunologic changes, supporting its clinical effectiveness.

Reduced Burden: Fewer clinic visits and simplified dosing schedules reduce the burden on families and healthcare systems, making low-dose P-OIT a practical alternative for widespread implementation.

Future Directions

While the results are promising, further research is needed to determine the long-term sustainability of low-dose P-OIT and its impact on sustained unresponsiveness after treatment cessation. The trial also raises questions about the minimum effective dose required for clinical benefit and the potential role of low-dose P-OIT in combination with other immunotherapy strategies, such as sublingual immunotherapy.

Additionally, further studies could explore whether starting with a low-dose maintenance regimen and increasing only if necessary may optimize the risk-benefit balance, particularly for patients with high baseline sensitivity or those at greater risk of adverse reactions.

Conclusion

This study provides strong evidence that low-dose peanut oral immunotherapy at 30 mg daily is a safe and effective option for children with peanut allergy. By increasing the threshold of reaction to clinically meaningful amounts of peanut protein, low-dose P-OIT reduces the risk of accidental reactions and promotes immunologic desensitization. Compared to higher-dose protocols, the low-dose approach offers improved safety, simplicity, and adherence, making it a promising option for broader clinical use.

These findings challenge the traditional notion that high doses are necessary for effective desensitization and open the door for more accessible, patient-friendly P-OIT protocols. Families and clinicians can be reassured that even minimal daily exposure can provide significant protection, potentially transforming the management of peanut allergy.

Sources

• Upton J. E. M., Toscano-Rivero D., Ke D., et al. Peanut Oral Immunotherapy Using 30 and 300 mg Maintenance Doses. The Journal of Allergy and Clinical Immunology: In Practice, 2026; 14(1).

Disclaimer

This blog is for informational purposes only and does not constitute medical advice. Patients should consult with a qualified healthcare professional before starting or modifying any treatment for peanut allergy or other medical conditions.